Skip to main content
. 2015 Dec 22;10(12):e0145291. doi: 10.1371/journal.pone.0145291

Fig 6. Effect of delphinidin and VEGF on ERK1/2 (Fig 6A), p38 MAP kinase activation (Fig 6B), CREB (Fig 6C) and ATF1 (Fig 6D) transcription factor activation.

Fig 6

HUVECs were treated for 30 minutes with or without 10 μg/ml delphinidin, in absence or presence of 10 ng/ml VEGF. Analysis of 30 μg protein was performed in each condition. (A) Densitometry represents the ratio of phosphorylated (a) over total (b) ERK1/2 and is expressed in % of control (n = 4). In comparison with control: * (P < 0.05), ** (P < 0.01), *** (P < 0.001). In comparison with VEGF: ## (P < 0.01). (B) Densitometry represents the ratio of phosphorylated (a) over total (b) p38 and is expressed in % of control (n = 4). In comparison with control: ** (P < 0.01). In comparison with VEGF: # (P < 0.05). (C) Densitometry represents the ratio of phosphorylated (a) over total (b) CREB and is expressed in % of control (n = 4). In comparison with control: * (P<0.05). In comparison with VEGF: # (P<0.05). (D) Densitometry represents the ratio of phosphorylated ATF1 (a) over total CREB (b) and is expressed in % of control (n = 4). In comparison with control: **** (P < 0.0001). In comparison with VEGF: ## (P < 0.01).